Transplantation immunology

被引:43
作者
VanBuskirk, AM
Pidwell, DJ
Adams, PW
Orosz, CG
机构
[1] JEWISH HOSP, TISSUE TYPING LAB, LOUISVILLE, KY 40202 USA
[2] OHIO STATE UNIV, CLIN HISTOCOMPATIBIL LAB, COLUMBUS, OH 43210 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1997年 / 278卷 / 22期
关键词
D O I
10.1001/jama.278.22.1993
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The practice of clinical and experimental transplantation continues to evolve at a rapid pace. To appreciate the current transplant practices, it is first necessary to review transplant immunology in its proper context, ie, as a component of the complex series of events that promote the repair of damaged tissues. These processes are generally catagorized as inflammation, immunity, and tissue repair/reinforcement. In general, there are 3 forms of graft rejection:hyperacute, acute, and chronic rejection. All 3 forms of graft rejection represent pathologic consequences of one or more of these repair-related processes. The various graft rejection responses also illustrate several complex immunologic principles that need to be considered. These include the definition of an alloantigen, the structure and function of major histocompatibility complex molecules, and the behavior of antigen-presenting cells and alloreactive T cells. This review combines these concepts and principles into a discussion of the 3 forms of graft rejection, each of which is addressed at the level of histopathology, pathobiology, incidence, and clinical strategies.
引用
收藏
页码:1993 / 1999
页数:7
相关论文
共 72 条
[11]  
BRADLEY JA, 1992, TRANSPLANT REV, V6, P115
[12]   LABORATORY AND CLINICAL MANAGEMENT OF THE HIGHLY SENSITIZED ORGAN TRANSPLANT RECIPIENT [J].
BRAUN, WE .
HUMAN IMMUNOLOGY, 1989, 26 (04) :245-260
[13]   Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: Tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide [J].
Brazelton, TR ;
Morris, RE .
CURRENT OPINION IN IMMUNOLOGY, 1996, 8 (05) :710-720
[14]   3-DIMENSIONAL STRUCTURE OF THE HUMAN CLASS-II HISTOCOMPATIBILITY ANTIGEN HLA-DR1 [J].
BROWN, JH ;
JARDETZKY, TS ;
GORGA, JC ;
STERN, LJ ;
URBAN, RG ;
STROMINGER, JL ;
WILEY, DC .
NATURE, 1993, 364 (6432) :33-39
[15]  
Brown MA, 1997, CRIT REV IMMUNOL, V17, P1
[16]   IMMUNOGLOBULIN CLASS AND SPECIFICITY OF ANTIBODIES CAUSING POSITIVE T-CELL CROSS-MATCHES - RELATIONSHIP TO RENAL-TRANSPLANT OUTCOME [J].
CHAPMAN, JR ;
TAYLOR, CJ ;
TING, A ;
MORRIS, PJ .
TRANSPLANTATION, 1986, 42 (06) :608-613
[17]   HOW ALPHA-BETA-T-CELL RECEPTORS SEE PEPTIDE MHC COMPLEXES [J].
CHIEN, YH ;
DAVIS, MM .
IMMUNOLOGY TODAY, 1993, 14 (12) :597-602
[18]   Allogeneic class I mhc requirement for alloantigen-reactive helper T-lymphocyte responses in vivo - Evidence for indirect presentation of alloantigen [J].
Clement, JD ;
Chan, SY ;
Bishop, DK .
TRANSPLANTATION, 1996, 62 (03) :388-396
[19]  
Cotran RS, 1994, PATHOLOGIC BASIS DIS, P51
[20]   GENERATION OF POLARIZED ANTIGEN-SPECIFIC CD8 EFFECTOR POPULATIONS - RECIPROCAL ACTION OF INTERLEUKIN (IL)-4 AND IL-12 IN PROMOTING TYPE-2 VERSUS TYPE-1 CYTOKINE PROFILES [J].
CROFT, M ;
CARTER, L ;
SWAIN, SL ;
DUTTON, RW .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (05) :1715-1728